Advaned Medical Isotope Corp said Wednesday it hired medical device, pharma and biotech-focused investor relations firm Circadian Group.
Newly-retained Circadian group will focus on presenting AMIC’s past success, current corporate profile and future catalysts to potential international investors.
“Circadian Group is an excellent fit for AMIC. Circadian’s expertise in our industry at our stage of development, along with outstanding recommendations from current and past clients contributed to our decision to retain them. We believe that 2016 is going to be a pivotal year for AMIC, and we feel confident that Circadian is a strong and proven partner to help us educate the public on what we have accomplished and where we plan to take the Company in the future,” AMIC CEO James Katzaroff said in a press release.
Kennewick, Wash.-based AMIC said Circadian uses the “most modern techniques in procuring interest in exciting and rapidly growing companies” such as itself. AMIC is a late-stage medical device development company focused primary on brachytherapy products, which deliver radiotherapy from inside the body by placing a radioactive source directly into or beside a tumor.
“AMIC fits our firm’s mission statement to a tee – working with small cap companies in the latter stages of early growth which are working toward a near-term transformational catalyst– as the firm works towards potential approval from the FDA on their 3 revolutionary products. Some of the best ideas and businesses are ones who re-engineer a “better mousetrap,” and AMIC far exceeds simple betterment of brachytherapy and therapeutic isotopes delivery devices. Y-90 appears to have a relatively superior efficacious therapeutic index while limiting collateral damage which is optimized by AMIC’s patented delivery techniques and method of action. In simpler terms, the suite of Y-90 products appear to be more effective and safer than competing products which, in our opinion, is how you disrupt and capture an entire industry. We are very optimistic for the future of AMIC in not only their business prospects but also in the quest to help cancer patients live a longer, less painful life,” Circadian managing director Tyler Troup said in prepared remarks.
